Discovery of dengue virus inhibitors

Abdullah, Adib Afandi and Lee, Yean Kee and Chin, Sek Peng and Lim, See Khai and Lee, Vannajan Sanghiran and Othman, Rozana and Othman, Shatrah and Abdul Rahman, Noorsaadah and Yusof, Rohana and Heh, Choon Han (2020) Discovery of dengue virus inhibitors. Current Medical Chemistry, 27 (30). pp. 4945-5036. ISSN 0929-8673, DOI

Full text not available from this repository.


To date, there is still no approved anti-dengue agent to treat dengue infection in the market. Although the only licensed dengue vaccine, Dengvaxia is available, its protective efficacy against serotypes 1 and 2 of dengue virus was reported to be lower than serotypes 3 and 4. Moreover, according to WHO, the risk of being hospitalized and having severe dengue increased in seronegative individuals after they received Dengvaxia vaccination. Nevertheless, various studies had been carried out in search of dengue virus inhibitors. These studies focused on the structural (C, prM, E) and non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5) of dengue virus as well as host factors as drug targets. Hence, this article provides an overall up-to-date review of the discovery of dengue virus inhibitors that are only targeting the structural and non-structural viral proteins as drug targets.

Item Type: Article
Funders: Universiti Malaya (UMRG-RP027A-15AFR), Universiti Malaya (PG046-2016A)
Uncontrolled Keywords: Drug discovery; Dengue virus; Virus inhibitors; Structural proteins; Non-structural proteins; Drug targets
Subjects: Q Science > Q Science (General)
R Medicine > R Medicine (General)
Divisions: Faculty of Medicine
Faculty of Science
Depositing User: Ms Zaharah Ramly
Date Deposited: 15 Dec 2022 08:26
Last Modified: 15 Dec 2022 08:26

Actions (login required)

View Item View Item